Quintiles and Allscripts have entered a strategic partnership to jointly develop software solutions to improve the drug development process and demonstrate the value of biopharma products.
 
The goal is to develop products that significantly reduce some of the bottlenecks associated with clinical research, outcomes, education and proof of new compound safety, effectiveness and value, according to a joint statement. Areas of focus include late-phase research, recruiting for and monitoring of clinical trials, and post-market surveillance.
 
The partnership’s objective is to create new solutions to enable customers to leverage de-identified longitudinal data from many sources in a HIPAA-compliant manner. This data could enable companies to improve the efficiency of processes involved in the development and evaluation of new drugs.
 
“This partnership with Allscripts is further proof of Quintiles’ ability to apply our industry-leading expertise to solve thorny industry problems, enabled by technology,” said Quintiles vice president, R&D Innovation, IT, Gavin Nichols. “We are very pleased to be partnering with industry leading Allscripts. We believe biopharma, patients, providers and payers all will benefit from the technology solutions that grow from this undertaking.”
 
“Everyone benefits from a faster, more efficient drug development process, and many of the practices and hospitals we work with have been asking us to help them to better collaborate with the variety of research opportunities now presenting themselves,” said Steven Schwartz, senior vice president of Corporate Business Development for Allscripts. “We believe this relationship will result in bringing new drugs and discoveries to market faster to improve patient care.